

HEMO ORGANIC LIMITED

CIN - L24231GJ1992PLC018224

Address: Shop 1 to 3, First floor, Piyu Apartment Opp Electricity Sub Station & Mahesh Nagar, Nr. Radhika Chambers & Jay Amarnath Society, Nikol Gam Road, Uttamnagar, Ahmedabad, Gujarat, India – 382 350

Email ID: hemoorganic@gmail.com **Website:** www.hemoorganic.co **Ph. No.** 8238557874

Date: 17th October, 2026

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai – 400 001

Dear Sir/Ma'am,

Sub: Submission of Un-audited Financial Results along with Limited Review Report thereon for the Quarter and half year ended on 30th September, 2026

Ref: Scrip Code: 524590 | Symbol: HEMORGANIC | ISIN: INE422G01015

In reference to captioned subject and pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the Un-audited Financial Results along with Limited Review Report, by the Statutory Auditor of the Company, i.e., M/s. V S S B & Associates, Chartered Accountant, for the quarter and half year ended on 30th September, 2026.

Please take note of the same and oblige.

For, Hemo Organic Limited

VISHWAMBAR
KAMESHWAR
SINGH

Digitally signed by
VISHWAMBAR
KAMESHWAR SINGH
Date: 2026.10.17
18:56:28 +05'30'

Vishwambar Kameshwar Singh
Managing Director
DIN: 09822587

Hemo Organic Limited

CIN No. L24231GJ1992PLC018224


Registered Office: Shop 1-3, 1 Floor, Piyu apartment, Opp. Electricity sub station, Jay amarnath society, Nikol, Ahmedabad, Gujarat, India, 382350

UNAUDITED FINANCIAL RESULTS (STAND ALONE) FOR THE QUARTER ENDED ON SEPTEMBER 30, 2026

(Rs. in lakhs)


Sr. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2026 (Unaudited)	30.06.2026 (Unaudited)	30.09.2025 (Unaudited)	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
I.	INCOME						
	(a) Revenue from operations	142.90	-	0.01	142.90	0.20	92.90
	(b) Other Income	-	-	-	-	-	0.20
	Total Income	142.90	-	0.01	142.90	0.20	93.10
II.	EXPENSES						
	(a) Purchases of Stock-in-trade	140.00	-	-	140.00	31.14	2.13
	(b) Changes in stock of finished goods, work-in-progress and stock-in-trade	-	-	0.01	-	(30.99)	90.80
	(c) Employee benefit expense	1.56	1.36	1.54	2.92	4.39	6.53
	(d) Finance costs	-	-	-	-	-	-
	(e) Depreciation and amortisation expense	0.01	0.01	0.02	0.02	0.03	0.06
	(f) Other expenses	0.80	6.05	2.56	6.85	11.20	43.41
	Total Expenses (a to g)	142.37	7.42	4.13	149.79	15.77	142.93
III.	Profit before exceptional items and tax (I) - (II)	0.53	(7.42)	(4.12)	(6.89)	(15.57)	(49.83)
IV.	Exceptional Items	-	-	-	-	-	-
V.	Profit before tax (III) - (IV)	0.53	(7.42)	(4.12)	(6.89)	(15.57)	(49.83)
VI.	Tax Expense						
	(a) Current tax	-	-	-	-	-	-
	- Current year	-	-	-	-	-	0.05
	- Prior years	-	-	-	-	-	-
	- MAT Credit (Entitlement)	-	-	(1.03)	-	(3.91)	27.93
	(b) Deferred tax	-	-	(1.03)	-	(3.91)	27.98
	Total tax expense	0.53	(7.42)	(3.09)	(6.89)	(11.66)	(77.81)
VII.	Profit after tax for the period (V) - (VI)						
VIII.	Other comprehensive income						
	Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	Remeasurement of the defined benefit liabilities	-	-	-	-	-	-
	Equity instruments through other comprehensive income	-	-	-	-	-	-
	Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	Other comprehensive income, net of tax	0.53	(7.42)	(3.09)	(6.89)	(11.66)	(77.81)
IX.	Total comprehensive income for the period						
X.	Paid up equity share capital (Face value of Rs. 10 each)	686.59	346.59	346.59	686.59	346.59	346.59
XI.	Reserves i.e. Other Equity	-	-	-	-	-	(439.55)
XII.	Earnings per equity share (Face value of Rs. 10 each)						
	(1) Basic	0.01	(0.21)	(0.09)	(0.19)	(0.34)	2.24
	(2) Diluted	0.01	(0.21)	(0.09)	(0.19)	(0.34)	2.24

Date: 17/10/2026
Place: Ahmedabad



By order of the Board
Hemo Organic Limited

Vishwambar Singh
DIN : 09822587
Managing Director

STATEMENT OF ASSETS AND LIABILITIES		
(Rs. in lakhs)		
Particulars	As at 30th September 2026	As at 31st March 2026
ASSETS		
1) Non-current assets		
(a) Property, Plant and Equipment	0.27	0.29
(b) Capital work-in-progress	-	-
(c) Intangible assets under development	-	-
(d) Financial Assets	-	-
(i) Investments	-	-
(ii) Loans	-	-
(iii) Other Financial Assets	-	-
(e) Deffered Tax Assets	-	-
(f) Other Non - Current Assets	-	-
2) Current assets		
(a) Inventories	50.83	50.83
(b) Financial Assets	-	-
(i) Trade receivables	235.76	238.86
(ii) Cash and cash equivalents	1.28	1.09
(iii) Bank balances other than (ii) above	-	-
(iv) Loans	77.07	86.18
(v) Other Financial Assets	-	-
(c) Current tax assets	0.05	-
(d) Other current assets	110.54	68.86
Total Assets	475.80	446.11
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	686.59	346.59
(b) Money received against share warrents	-	106.25
(c) Other Equity	(361.44)	(439.55)
LIABILITIES		
1) Non-current liabilities		
(a) Financial Liabilities	-	-
(i) Borrowings	129.11	274.06
(ii) Other financial liabilities (other than those specified in item (b), to be specified)	-	-
(b) Provisions	-	-
(c) Deferred tax liabilities (Net)	0.05	0.05
2) Current liabilities		
(a) Financial Liabilities	-	-
(i) Borrowings	-	-
(ii) Trade payables	19.22	156.12
(iii) Other financial liabilities	1.41	1.41
(b) Other current liabilities	0.56	0.58
(c) Provisions	0.30	0.60
(d) Current Tax Liabilities (Net)	-	-
Total Equity and Liabilities	475.80	446.11
Date: 17/10/2026 Place: Ahemdabad  By order of the Board Hemo Organic Limited  Vishwambar Singh DIN : 09822587 Managing Director		

Cash flow Statement For the period ended 30th September,2026

(Rs. in lakhs)

Sr No.	Particulars	For the half year ended September, 2026	For the year ended September, 2025
A.	Cash flow from operating activites		
	Net profit before tax	(6.89)	(15.57)
	Non Cash Income	-	-
	Depreciation	0.02	0.02
	Operating profit before working capital changes	(6.87)	(15.55)
	Net Changes in :-		
	(Increase)/ decrease in Operating Assets:		
	- Inventories	-	(30.99)
	- Trade Receivables	3.10	(0.07)
	- Other Non - Current Assets	-	-
	- Other Current Assets	(41.73)	(2.39)
	Increase/ (decrease) in other current liabilities		
	- Long - Term Provisions	-	-
	- Trade Payables	(136.90)	31.92
	- Short - Term Provisions	(0.30)	(0.30)
	- Other Financial Liabilities	-	-
	- Other Current Liabilities	(0.02)	0.57
	Cash generated from operations	(182.72)	(16.81)
	Income tax paid	-	-
	Net cash inflow/(outflow) from operating activities (A)	(182.72)	(16.81)
B.	Cash flow from investing activites		
	- Payments for Property,Plant & Equipments	-	(0.15)
	- Decrease in Loans & Advances	9.11	-
	Net cash inflow / (outflow) from investing activities (B)	9.11	(0.15)
C.	Cash inflow/(outflow) from financing activities		
	- Repayment of borrowings	-	-
	Increase in Equity Share capital	318.75	-
	- Financial expenses	-	-
	- Loan Taken	(144.95)	16.14
	Net cash inflow / (outflow) used in financing activities (C)	173.80	16.14
	Net changes in cash and cash equivalents (A+B+C)	0.19	(0.82)
	Opening Cash and cash equivalents	1.09	0.87
	Closing Cash and cash equivalents	1.28	0.05

Date: 17/10/2026
Place: Ahemdabad



By order of the Board
Hemo Organic Limited

Vishwambar Singh
DIN : 09822587
Managing Director

Notes :

- 1 The Company operates in a single segment . As per Ind AS 108 on segment reporting issued by the ICAI, the same is considered to constitute as single primary segment. Accordingly, the disclosure requirements of Ind AS 108 are not applicable.
- 2 The above standalone financial results were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 17 Oct, 2026.
- 3 The financial results of the company have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the companies Act, 2013 read with relevant rules there under and in terms with regulation 33 of SEBI (Listing Obligation and Disclosures Requirements) regulations 2015 and SEBI circular dated 5th July 2016.
- 4 Earning per share for the quarter and year ended has been calculated as per weighted average formula and diluted Earning per share has been calculated considering proposed issue of equity shares on account of conversion of convertible securities.
- 5 Previous period figures have been regrouped and rearranged, whenever considered necessary.
- 6 There are no associates, subsidiaries, joint ventures of the company and hence consolidated results are not applicable.

Date: 17/10/2026

Place: Ahemdabad



**By order of the Board
Hemo Organic Limited**

A handwritten signature in blue ink, appearing to read "Vishwambar Singh".

**Vishwambar Singh
DIN : 09822587
Managing Director**

INDEPENDENT AUDITOR'S REVIEW REPORT

Limited Review Report on Standalone Quarter & half year Ended as on 30th September, 2026 Unaudited Financial Results of the company pursuant to Regulation 33 of the SEBI (listing Obligation and Disclosure Requirements) Regulations, 2015.

To,

The Board of Directors,
HEMO ORGANIC LIMITED

We have reviewed the accompanying statement of unaudited financial results of M/s HEMO ORGANIC LIMITED for the quarter ended 30th September, 2026, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FCA/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard (Ind AS) 34 on 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, except as specified in Qualified Opinion para, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and



Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Qualified Opinion:

1. We have not been provided with the balance confirmation or any other details for the trade receivable & trade payable in the books of accounts & in the absence of the same we are unable to confirm the balance and nature of the transactions.

Date: 17/10/2026
Place: Ahmedabad



UDIN: 26138132TUZRET5133

For, V S S B & Associates
Chartered Accountants
Firm Registration No. 121356W

Shridhar

Shridhar Shah
Partner
Membership No. 138132

HEMO ORGANIC LIMITED

CIN - L24231GJ1992PLC018224

Address: Shop 1 to 3, First floor, Piyu Apartment Opp Electricity Sub Station & Mahesh Nagar, Nr. Radhika Chambers & Jay Amarnath Society, Nikol Gam Road, Uttamnagar, Ahmedabad, Gujarat, India – 382 350

Email ID: hemoorganic@gmail.com **Website:** www.hemoorganic.co **Ph. No.** 8238557874

Date: 17th October, 2026

To,
BSE Limited
Phiroze Jeejeebhoy
Tower, Dalal Street,
Mumbai – 400001.

Dear Sir / Madam,

Sub: Statement on deviation(s) / variation(s) in utilization of proceeds raised through Preferential Issue of convertible warrants, pursuant to Regulation 32 of SEBI (LODR) Regulations, 2015 ("SEBI Listing Regulations) for the quarter ended on September 30, 2026.

Ref: Scrip Code: 524590 | Scrip Symbol: HEMORGANIC | ISIN: INE422G01015

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the statement, in the prescribed format, confirming that there were no deviations or variations in the utilization of proceeds from the Preferential Issue of Convertible Warrants of the Company for the quarter ended September 30, 2026. The said statement was duly reviewed by the Audit Committee at its meeting held today, i.e., 17th October, 2026.

You are requested to kindly take the above information on record.

Thanking You,

For, HEMO ORGANIC LIMITED

VISHWAMBAR
KAMESHWAR SINGH

Digitally signed by VISHWAMBAR
KAMESHWAR SINGH
Date: 2026.10.17 18:57:00 +05'30'

VISHWAMBAR KAMESHWAR SINGH
MANAGING DIRECTOR
DIN: 09822587

**STATEMENT OF DEVIATION OR VARIATION FOR PROCEEDS OF PREFERENTIAL ISSUE OF
CONVERTIBLE WARRANTS:**

Name of listed entity	Hemo Organic Limited
Mode of Fund Raising	Preferential Issue of Convertible Warrants
Date of Raising Funds	17-09-2026
Amount Raised	Rs. 2,76,25,000
Report filed for Quater ended	30 th September, 2026
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change interms of a contract or objects, which was approved by the Shareholders	Not Applicable
If Yes, Date of Shareholders Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	None
Comments of the auditors, if any	None
Objects for which funds have been raised in the Preferential Issue and details of deviation,if any, in the following table:	

(Rs. In lakhs)

Sr. No.	Object as disclosed in the offer document	Modified Object, if Any	Original Allocation	Modified allocation, if Any	Amount utilised	Unutilised Amount	Amount of Deviation/ Variation for the Quarter	Remarks, if any
1	Working Capital Requirement	NA	318.75	NA	207.19	0	NA	NA
2	General Corporate Purpose	NA	106.25	NA	69.06	0	NA	NA
			425.00		276.25	0		

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which funds have been raised; or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed; or
- (c) Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc.

FOR, HEMO ORGANIC LIMITED

VISHWAMBAR Digitally signed by
VISHWAMBAR

KAMESHWAR KAMESHWAR SINGH

SINGH Date: 2026.10.17
18:57:22 +05'30'

VISHWAMBAR KAMESHWAR SINGH

MANAGING DIRECTOR

DIN: 09822587

STATEMENT OF DEVIATION OR VARIATION FOR PROCEEDS OF PREFERENTIAL ISSUE OF CONVERTIBLE WARRANTS:

Name of listed entity	Hemo Organic Limited
Mode of Fund Raising	Preferential Issue of Convertible Warrants
Date of Raising Funds	25-09-2026
Amount Raised	Rs. 42,50,000
Report filed for Quater ended	30 th September, 2026
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change interms of a contract or objects, which was approved by the Shareholders	Not Applicable
If Yes, Date of Shareholders Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	None
Comments of the auditors, if any	None
Objects for which funds have been raised in the Preferential Issue and details of deviation,if any, in the following table:	

(Rs. In lakhs)

Sr. No.	Object as disclosed in the offer document	Modified Object, if Any	Original Allocation	Modified allocation, if Any	Amount utilised	Unutilised Amount	Amount of Deviation/ Variation for the Quarter	Remarks, if any
1	Working Capital Requirement	NA	318.75	NA	31.87	-	NA	NA
2	General Corporate Purpose	NA	106.25	NA	9.54	1.09	NA	An amount of Rs. 109,000 earmarked for General Corporate Purpose ("GCP") remains unutilised and shall be deployed/adjusted as and when required towards General Corporate Purpose.
			425.00		41.41	1.09		

Notes:

- On February 26, 2026, the Company allotted 34,00,000 Convertible Equity Share Warrants on a preferential basis to non-promoter allottees, pursuant to the approval granted by the shareholders at the Extra-Ordinary General Meeting held on January 07, 2026. Each warrant was issued at an issue price of ₹12.50/- (Rupees Twelve and Fifty Paise only), comprising a face value of ₹10.00/- and a premium of ₹2.50/- per warrant.
- The Company had received an amount of ₹1,06,25,000/- (Rupees One Crore Six Lakh Twenty-Five Thousand only), representing 25% of the total issue price, from the allottees towards the subscription of warrants on February 26, 2026. The company has received the balance amount of ₹3,18,75,000/- (Rupees Three Crore Eighteen Lakh Seventy-Five Thousand only), representing the remaining 75% of the total issue price, during the quarter.

3. Upon receipt of the full issue consideration, the Company converted the aforesaid 34,00,000 Convertible Equity Share Warrants into an equivalent number of equity shares and allotted 34,00,000 equity shares to the respective warrant holders on September 25, 2026. The equity shares so allotted rank pari passu in all respects with the existing equity shares of the Company.

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which funds have been raised; or
(b) Deviation in the amount of funds actually utilized as against what was originally disclosed; or
(c) Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc.

FOR, HEMO ORGANIC LIMITED

VISHWAMBAR
KAMESHWAR
SINGH

Digitally signed by
VISHWAMBAR
KAMESHWAR SINGH
Date: 2026.10.17 18:57:47
+05'30'

VISHWAMBAR KAMESHWAR SINGH
MANAGING DIRECTOR
DIN: 09822587

UTILIZATION OF FUNDS CERTIFICATE
M/s. Hemo Organic Limited

To,
The Board of Directors,
Hemo Organic Limited

Respected Sir,

Subject: Certificate pursuant to SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 in relation to the proceeds of the issue from the Preferential Issue of Convertible Warrants for Hemo Organic Limited ("the Company")

We have been requested to certify the utilisation of the proceeds of the issue from the Preferential Issue of 34,00,000 Convertible Warrants. For the purpose of certifying the below table, we have reviewed documents, statement, papers, books of accounts, and other relevant information of the Company on the proceeds of Preferential Issue of Convertible Warrants. Based on our review of the same, we hereby certify below:

Objects for which funds have been raised and utilisation thereof:

(Rupees in Lakhs)

Sr. No.	Object as disclosed in the offer document	Original Allocation	Amount utilised till September 30, 2026	Unutilised Amount as on September 30, 2026
1	Working Capital Requirement	318.75	318.75	-
2	General Corporate Purpose	106.25	105.16	1.09
		425.00	423.91	1.09

We wish to inform you that there has been no deviation(s) or variation(s) in the use of Preferential Issue of Convertible Warrants proceeds of the Issue, raised from Convertible Warrants by the Company for the quarter ended September 30, 2026.


Notes:

- On February 26, 2026, the Company allotted 34,00,000 Convertible Equity Share Warrants on a preferential basis to non-promoter allottees, pursuant to the approval granted by the shareholders at the Extra-Ordinary General Meeting held on January 07, 2026. Each warrant was issued at an issue price of ₹12.50/- (Rupees Twelve and Fifty Paise only), comprising a face value of ₹10.00/- and a premium of ₹2.50/- per warrant.
- As on the reporting date, the Company had received an aggregate amount of ₹4,25,00,000/- (Rupees Four Crore Twenty-Five Lakh only), representing 100% of the total issue consideration payable in respect of the aforesaid 34,00,000 warrants.

HEAD OFFICE: A/912, 9th Floor, Ratnaakar Nine Square, Opp. ITC Narmada Hotel, Vastrapur, Ahmedabad - 380015, GJ

BRANCH: 108, Sunrise Mall, Nr. Mansi Cross Roads, Judges Bungalow Road, Vastrapur, Ahmedabad - 380015, GJ

HO: (o) +91 93777 71182 (e) cavishves@gmail.com | Branch: (o) +91 91063 06216 (e) cashridhar@gmail.com



3. Upon receipt of the full issue consideration, the Company converted the aforesaid 34,00,000 Convertible Equity Share Warrants into an equivalent number of equity shares and allotted 34,00,000 equity shares to the respective warrant holders on September 25, 2026. The equity shares so allotted rank pari passu in all respects with the existing equity shares of the Company.

Date: 17/10/2026

Place: Ahmedabad



UDIN: 26138132XSEOTH2773

For, V S S B & Associates

Chartered Accountants

Firm Registration No. 121356W

Shridhar Shah

Partner

Membership No. 138132